KMID : 0361620240590010022
|
|
Journal of the Korean Orthopaedic Association 2024 Volume.59 No. 1 p.22 ~ p.32
|
|
Comparative Evaluation of Second-Line Chemotherapy Agents for Advanced Soft Tissue Sarcoma: Gemcitabine/Docetaxel, Pazopanib, and Alternatives
|
|
Kim Tae-Hun
Sung Ki-Hyuk Chung So-Hak
|
|
Abstract
|
|
|
Purpose: Soft tissue sarcomas (STS) are a group of rare mesenchymal cancers with more than 50 histological subtypes. A recently published study identified the chemosensitivity according to the tumor subtype and grade. This study assessed the efficacy of gemcitabine/docetaxel (GD) and other agents by comparing the results with the literature.
Materials and Methods: One hundred and eight patients with STS were enrolled between May 2012 and February 2020. Sixteen cases (16 patients) received second-line pazopanib or GD for advanced STS. The progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier product-limit method. The overall response rate (ORR) was determined based on the proportion of individuals within a treatment group who achieved either a partial response or complete response to the treatment within a specific timeframe. The quality of life of the patients before and after chemotherapy was evaluated using the EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) questionnaire.
Results: Pazopanib yielded a median OS of 13.2 months and a median PFS of 10.8 months at the authors¡¯ institution. The median OS and PFS for GD were 16.0 and 12.9 months, respectively. In the present 16 assessable cases, GD and pazopanib achieved a 37.5% ORR. After chemotherapy, the EORTC QLQ-C30 functional scale score improved in both groups, but the difference was not statistically significant.
Conclusion: Pazopanib and GD may be effective second-line treatments for improving the OS and PFS. GD was as better OS and ORR than pazopanib in patients with advanced STS and appeared more efficient.
|
|
KEYWORD
|
|
sarcoma, gemcitabine, docetaxel, pazopanib
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|